

# Global Pulmonary Drugs Market 2026

<https://marketpublishers.com/r/G81318B48C57EN.html>

Date: August 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: G81318B48C57EN

## Abstracts

The Global Pulmonary Drugs Market was valued at in and is anticipated to reach by , at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Pulmonary Drugs Market.

This report delivers a comprehensive overview of the Global Pulmonary Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Pulmonary Drugs Market. The Global Pulmonary Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Global Pulmonary Drugs Market Scope:

By Drug Class

Inhaled Corticosteroids (ICS)

Long-Acting Beta2-Agonists (LABA)

Antihistamines

Vasodilators

Short-Acting Beta2-Agonists (SABA)

Anticholinergics

Combination Drugs

#### By Application

Asthma & COPD

Allergic Rhinitis

Pulmonary Arterial Hypertension

Cystic Fibrosis

#### By Distribution Channel

Hospitals Pharmacy

Retail Pharmacy

E-commerce

#### Major Highlights

This report delivers a comprehensive overview of the Global Pulmonary Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Pulmonary Drugs Market. The Global Pulmonary Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

### Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with

industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. MARKET DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Market Snippet By Drug Class
- 3.2. Market Snippet By Application
- 3.3. Market Snippet By Distribution Channel
- 3.4. Market Snippet by Region

### **4. MARKET DYNAMICS**

- 4.1. Market Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Rising incidences of chronic respiratory diseases will drive the market growth
    - 4.1.1.2. The surge in smokers around the world is driving the market growth
  - 4.1.2. Restraints:
    - 4.1.2.1. The availability of counterfeit drugs is likely to hamper market growth
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Unmet Needs

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of Covid-19 on the Market

- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

## **7. BY DRUG CLASS**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  - 7.1.2. Market Attractiveness Index, By Drug Class Segment
- 7.2. Inhaled Corticosteroids (ICS)\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 7.3. Long-Acting Beta2-Agonists (LABA)
- 7.4. Antihistamines
- 7.5. Vasodilators
- 7.6. Short-Acting Beta2-Agonists (SABA)
- 7.7. Anticholinergics
- 7.8. Combination Drugs

## **8. BY APPLICATION**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  - 8.1.2. Market Attractiveness Index, By Application
- 8.2. Asthma & COPD\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 8.3. Allergic Rhinitis
- 8.4. Pulmonary Arterial Hypertension
- 8.5. Cystic Fibrosis

## **9. BY DISTRIBUTION CHANNEL**

## 9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

9.1.2. Market Attractiveness Index, By Distribution Channel Segment

## 9.2. Hospitals Pharmacy \*

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028

## 9.3. Retail Pharmacy

## 9.4. E-commerce

# 10. BY REGION

## 10.1. Introduction

10.1.1. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region

10.1.2. Market Attractiveness Index, By Region

## 10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

## 10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. U.K.

10.3.6.3. France

10.3.6.4. Italy

10.3.6.5. Spain

10.3.6.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.4.6.1. Brazil

10.4.6.2. Argentina

10.4.6.3. Rest of South America

10.5. Asia Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.5.6.1. China

10.5.6.2. India

10.5.6.3. Japan

10.5.6.4. Australia

10.5.6.5. Rest of Asia Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

## **11. COMPETITIVE LANDSCAPE**

11.1. Key Developments and Strategies

11.2. Company Share Analysis

11.3. Product Benchmarking

11.4. List of key companies to watch

11.5. List of the company with disruptive technology

11.6. List of start-up companies

## **12. GLOBAL PULMONARY DRUGS MARKET- COMPANY PROFILES**

### 12.1. Circassia Pharmaceuticals Inc\*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Key Highlights

12.1.4. Financial Overview

### 12.2. AstraZeneca

### 12.3. F. Hoffmann-La Roche Ltd.

### 12.4. GlaxoSmithKline

### 12.5. Grifols

### 12.6. Merck & Co.

### 12.7. Pfizer

### 12.8. Regeneron Pharmaceuticals

### 12.9. Shanghai Sine Promod Pharmaceutical Co

### 12.10. Nuance Pharma Limited.(\*LIST NOT EXHAUSTIVE)

## **13. DATAM**

### 13.1. Appendix

### 13.2. About Us and Services

### 13.3. Contact Us

## I would like to order

Product name: Global Pulmonary Drugs Market 2026

Product link: <https://marketpublishers.com/r/G81318B48C57EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G81318B48C57EN.html>